Previous 10 | Next 10 |
2024-02-17 05:05:44 ET In 2023, revenue decreased by 2% due to lower sales in sequencing consumables and instruments. Operating expenses showed significant changes, impacting net income margin. Management focuses on strategic collaborations and cash management. Key performance indicators rema...
2024-02-15 01:30:00 ET Summary Vision Capital is fundamental-driven, bottom-up, and only focuses on investing in long-only publicly-listed equities. For 2023, Vision Capital returned +69.9% versus the S&P 500’s +24.0%. A large majority of our holdings were sold off ...
2024-02-14 17:06:13 ET More on Illumina Illumina, Inc. (ILMN) Q4 2023 Earnings Call Transcript Illumina: One Of The Most Hated Stocks In Healthcare Is Looking Like A Strong Buy Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024 Analyst rea...
2024-02-14 12:30:02 ET Stephens analyst issues BUY recommendation for ILMN on February 14, 2024 12:00PM ET. The previous analyst recommendation was Buy. ILMN was trading at $139.85 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...
NORTHAMPTON, MA / ACCESSWIRE / February 14, 2024 / Illumina: For the fifth year in a row, Illumina has been named one of America's Most JUST Companies by JUST Capital and CNBC . Illumina ranked #29, out of the top 100, and second in the pharmaceutical and biotech industry. Over 1,000 of the l...
2024-02-09 15:12:18 ET More on Illumina Illumina, Inc. (ILMN) Q4 2023 Earnings Call Transcript Illumina: One Of The Most Hated Stocks In Healthcare Is Looking Like A Strong Buy Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024 Illumina Q4...
2024-02-08 20:44:04 ET Illumina, Inc. (ILMN) Q4 2023 Earnings Conference Call February 8, 2024 5:00 PM ET Company Participants Salli Schwartz - Vice President, Investor Relations Jacob Thaysen - Chief Executive Officer Joydeep Goswami - Chief Financial Officer an...
2024-02-08 16:07:28 ET More on Illumina Illumina: One Of The Most Hated Stocks In Healthcare Is Looking Like A Strong Buy Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024 Concentric by Ginkgo and Illumina join hands for pathogen monitoring progr...
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023 PR Newswire Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat o...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...
News, Short Squeeze, Breakout and More Instantly...
Illumina to Present Upcoming Strategy Update PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24 , the company will present a Strategy Update on Tuesday, August 13, 2024 starting at ...
Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24 , the company will issue results for the second qu...
The Illumina iHope China program will provide 1800 families with genetic testing in 2024, broadening its reach and impact nationwide Originally published on Illumina News Center NORTHAMPTON, MA / ACCESSWIRE / July 11, 2024 / This year may be the most impactful yet in the short history o...